Chronic kidney disease patients with elevated calcium-phosphate product (CPP) — a biomarker reflecting disrupted mineral metabolism — faced significantly worse outcomes after coronary stent placement. Among matched cohorts, those with high CPP showed 43% higher all-cause mortality, 59% more in-stent blockages, and 49% more heart failure episodes over five years. This propensity-matched analysis of adult CKD patients undergoing percutaneous coronary intervention reveals how mineral imbalances drive cardiovascular complications beyond traditional risk factors. The calcium-phosphate product represents an underutilized prognostic tool that could transform pre-procedural risk assessment. Current cardiology practice focuses heavily on coronary anatomy while often overlooking metabolic derangements that fundamentally alter vessel biology. The findings suggest CPP monitoring could identify high-risk patients who might benefit from intensified mineral management or alternative revascularization strategies. However, this preprint awaits peer review, and the retrospective design limits causal inferences. The results are nonetheless compelling given the growing intersection of kidney disease and cardiovascular mortality in aging populations. This represents important but incremental progress in personalizing cardiac interventions for complex patients with multiple organ system dysfunction.